The Great Rescheduling What Cannabis Businesses Need to Know About the 2026 Federal Shift
After decades of prohibition, the United States stands on the cusp of one of the most significant shifts in federal drug policy since the Controlled Substances Act was enacted in 1970. On December 18, 2025, President Trump signed an executive order directing the Attorney General to complete the process for reclassifying marijuana under the federal Controlled Substances Act, moving it from Schedule I to Schedule III. While the formal rulemaking process remains ongoing and the effective date is likely still a year or more away, the direction of federal policy is now clear. This article examines what rescheduling actually means, where the process stands, and how cannabis businesses should prepare for the changes ahead.
Understanding the Shift From Schedule I to Schedule III
Under current federal law, marijuana is classified as a Schedule I controlled substance, a category reserved for drugs defined as having no accepted medical use and a high potential for abuse, the same classification as heroin and LSD. Schedule III, by contrast, includes drugs with accepted medical uses and a lower potential for physical and psychological dependence, such as ketamine and certain testosterone preparations.
The move to Schedule III formally acknowledges what state medical programs have demonstrated for years, that cannabis has legitimate therapeutic applications for conditions including anorexia and chronic pain. This recognition alone represents a fundamental shift in the federal governments posture toward the plant.
The Procedural Maze Where Things Stand Now
Despite the executive orders directive to proceed in the most expeditious manner, the rescheduling process remains procedurally complex and far from complete.
The Current Stalemate
The proposed rule to move marijuana to Schedule III was actually published back in May 2024. After the comment period closed, the process moved into a formal hearing phase but then stalled. As of early 2026, the proceeding remains frozen due to an interlocutory appeal inside the administrative process.
Legal expert Shane Pennington, who represented the sole pro-rescheduling industry party in that appeal, explains that the most efficient path forward would be for the administration to withdraw the hearing altogether and move directly toward a final rule based on the HHSs already established medical record. Pennington notes that something this big was going to get challenged and will get challenged regardless in federal court.
The Timeline Reality
For operators and investors making business decisions, understanding the realistic timeline is essential. The Illinois Lawyer Now blog provides a helpful planning framework. In a fast scenario, aggressive estimates point to early to mid 2027. The likely scenario for planning baseline purposes is late 2027. In a slow scenario involving procedural fights and stay risk, the date could slip to 2028 or later.
Even after a final rule is published, the Congressional Review Act imposes additional delays if the rule is designated major, which a Schedule III reclassification almost certainly would be given its projected 100 million plus annual economic effect.
The 800 Pound Gorilla Section 280E Tax Relief
For state legal cannabis operators, the most concrete and widely anticipated effect of Schedule III is the potential elimination of Internal Revenue Code Section 280E.
What 280E Does Now
Section 280E currently prohibits businesses trafficking in Schedule I or II substances from deducting ordinary business expenses. This means state legal cannabis companies can only deduct cost of goods sold, forcing them to pay federal income tax on gross income rather than net income. The result is effective tax rates that can soar to 70 to 90 percent, compared to the standard 21 percent corporate rate.
What Changes Under Schedule III
If marijuana moves to Schedule III, Section 280E should no longer apply. This would allow cannabis businesses to deduct ordinary and necessary expenses just like any other industry. Payroll and benefits. Rent and facilities costs. Marketing and advertising. Professional fees including legal, accounting, and consulting. Insurance and ordinary overhead.
For many operators, this tax relief would fundamentally transform balance sheets, improving cash flow, increasing valuation multiples, and enhancing access to capital.
A Critical Caution 280E Still Applies Today
Despite the optimism surrounding rescheduling, a recent warning from tax attorneys bears emphasis. Section 280E still applies right now. The IRS has made this clear in multiple guidance documents, stating that marijuana remains a Schedule I controlled substance and 280E applies until a final federal rule is published.
Some businesses have begun filing returns ignoring 280E or filing amended returns seeking refunds. The IRS has warned that the rationales being used do not constitute reasonable basis, a relatively high standard of tax reporting, and penalties may ensue. The prudent advice is to continue operating under 280E until a final rule is actually effective, and if you receive refunds, set that cash aside at least through the audit window.
What Rescheduling Does Not Fix
It is equally important to understand what Schedule III does not change. Rescheduling is not legalization, and many of the industrys most significant challenges will persist.
No Federal Legality for State Markets
State compliant cannabis activity will still exist in tension with federal law. Schedule III does not authorize state licensed operators to sell cannabis, nor does it create a lawful federal pathway for recreational adult use sales. The fundamental conflict between state and federal law remains unresolved.
No Interstate Commerce
Rescheduling alone does not permit operators to ship product across state lines. Multi state businesses must continue maintaining separate supply chains and state by state compliance operations.
Banking Improves But Doesnt Solve
While Schedule III may increase comfort for some financial institutions, core compliance issues tied to federal illegality and anti money laundering frameworks remain without legislative change. Full banking integration, access to traditional capital markets, and mainstream payment processors will likely remain limited.
Dan Ahrens, a managing director at AdvisorShares, suggests that rescheduling could make the SAFER Banking Act a much, much less controversial issue and more likely to pass as an administrative thing that needs to get done. But that would require separate congressional action.
Bankruptcy and IP Protections Remain Difficult
Bankruptcy access and federal trademark protections typically depend on lawful use in commerce under federal law. A Schedule III move alone is unlikely to deliver predictable outcomes in these areas.
The Ripple Effects What Else Rescheduling Unlocks
Research and Medical Legitimacy
Schedule III classification reduces federal hurdles for clinical trials by easing security requirements and compliance burdens for researchers. This paves the way for FDA approved cannabinoid treatments and creates a formal pipeline for medical legitimacy.
The executive order specifically directs HHS, FDA, and NIH to collaborate on research methods using real world evidence, including randomized controlled trials, longitudinal studies, and patient interviews, to inform clinical standards. This could position multi state operators as realistic acquisition targets for pharmaceutical companies seeking validated medical compounds.
Capital Markets Evolution
With normalized taxation and improved cash flows, cannabis companies may finally be able to uplist from OTC markets to major exchanges like NYSE or Nasdaq. Ahrens notes that exchanges have already begun reaching out to cannabis companies to discuss transition plans.
The removal of 280E is also expected to trigger significant M and A activity. Ahrens predicts the first thing US cannabis companies are going to do is pay down their debt, and he expects to see more M and A once everything is complete.
The Hemp Dimension A Complicating Factor
Any discussion of cannabis rescheduling would be incomplete without addressing the parallel upheaval in the hemp industry. The government funding bill enacted in late 2025 includes provisions that dramatically narrow the federal hemp definition, imposing new limits on total THC and certain synthetic cannabinoids.
The new law, which takes effect November 12, 2026, provides that legal hemp must contain no more than 0.4 milligrams of total THC per container, a standard that would effectively ban most full spectrum CBD products currently on the market. Industry stakeholders warn these revisions could eliminate up to 95 percent of the US hemp industry, currently estimated at approximately 28 billion dollars.
The executive order acknowledges this tension, directing the administration to work with Congress on preserving access to appropriate full spectrum CBD products while restricting those that pose serious health risks. How this balance is struck will determine whether the hemp industry survives its own regulatory compliance cliff.
Planning for 2026 and Beyond
For cannabis operators, investors, and advisors, the message from legal experts is consistent. Treat 2026 as a change in law year, but maintain realistic expectations about timing and scope.
Practical Steps for Businesses
First, model post 280E economics. Understand how normalized taxation would affect your financial statements, cash flow, and valuations.
Second, maintain compliance rigor. Even with rescheduling on the horizon, federal illegality persists. Keep compliance programs robust and documentation diligence ready.
Third, stress test contracts. Review agreements for shifting tax and regulatory assumptions and consider how timing uncertainty affects deal structures.
Fourth, prepare for a two track period. Operational planning should anticipate Schedule III benefits while acknowledging uncertainty about when finality arrives and whether court action affects implementation.
Fifth, monitor the procedural lane. Which path the Department of Justice chooses, whether completing the existing rulemaking, using treaty authority, or restarting the hearing track, will significantly affect timing.
Conclusion A Monumental Shift with Measured Expectations
The executive order directing marijuana rescheduling represents a genuine turning point in federal cannabis policy. For the first time, the federal government is poised to formally acknowledge what patients, physicians, and state regulators have long understood. Cannabis has accepted medical uses and belongs in a less restrictive regulatory category.
The practical consequences, particularly Section 280E tax relief, will fundamentally reshape the economics of state legal cannabis businesses. This will improve profitability, enable normal business deductions, and potentially unlock capital markets that have remained largely closed to the industry.
But rescheduling is not a panacea. It does not legalize cannabis, authorize interstate commerce, solve banking access, or resolve the fundamental tension between state and federal law. These challenges require legislative action that remains uncertain.
As legal expert Shane Pennington observes, the tables have turned for the industry and they are now going to be defending the hill. As a lawyer he says that feels amazing. For an industry long on the offensive, defending a favorable administrative record is indeed a remarkable position.
The effective date likely remains a year or more away, and litigation is all but certain. But the direction is now clear. Cannabis is moving toward Schedule III, and with it, the industry moves toward a new era of normalized operations, improved economics, and finally federal recognition of medical utility.
